EcoDrugPlus

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase, Catalytic Subunit Alpha

Ensembl ID : ENSIPUG00000003075
Gene Symbol: PIK3CA
3 Cross references
205 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase, Catalytic Subunit Beta

Ensembl ID : ENSIPUG00000009164
Gene Symbol: PIK3CB
3 Cross references
216 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase, Catalytic Subunit Delta

Ensembl ID : ENSIPUG00000003962
Gene Symbol: PIK3CD
3 Cross references
213 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase, Catalytic Subunit Gamma

Ensembl ID : ENSIPUG00000015194
Gene Symbol: PIK3CG
3 Cross references
213 Possible Orthologues:

Phosphodiesterase 10a

Ensembl ID : ENSIPUG00000017463
Gene Symbol: PDE10A
3 Cross references
205 Possible Orthologues:

Phosphodiesterase 3a, Cgmp-Inhibited

Ensembl ID : ENSIPUG00000014296
Gene Symbol: PDE3A
3 Cross references
215 Possible Orthologues:

Phosphodiesterase 3b

Ensembl ID : ENSIPUG00000003658
Gene Symbol: PDE3B
3 Cross references
217 Possible Orthologues:

Phosphodiesterase 4a

Ensembl ID : ENSIPUG00000013114
Gene Symbol: PDE4A
3 Cross references
201 Possible Orthologues:

Phosphodiesterase 4b

Ensembl ID : ENSIPUG00000013353
Gene Symbol: PDE4B
4 Cross references
225 Possible Orthologues:

Phosphodiesterase 4b, Camp-Specific A

Ensembl ID : ENSIPUG00000007480
Gene Symbol: PDE4BA
3 Cross references
228 Possible Orthologues:

Phosphodiesterase 4d

Ensembl ID : ENSIPUG00000015377
Gene Symbol: PDE4D
4 Cross references
157 Possible Orthologues:

Phosphodiesterase 4d, Camp-Specific

Ensembl ID : ENSIPUG00000008197
Gene Symbol: PDE4D
3 Cross references
235 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).